3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
34
Genitourinary
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Endocrine
1
Breast
1
Conditions
Sarcoma
2
Mesothelioma, Malignant
2
Unresectable Locally Advanced or Metastatic Solid Tumors
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Neoplasm Metastasis
1
MSI-H Colorectal Cancer
1
Gastro-enteropancreatic neuroendocrine tumor
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Anus Neoplasms
1
Advanced Refractory Solid Tumors
1
Interventions
Nivolumab
5
Ipilimumab
3
pembrolizumab
2
durvalumab
2
budigalimab
2
venetoclax
1
tislelizumab
1
spartalizumab
1
sargramostim
1
rovalpituzumab tesirine
1
regorafenib
1
obinutuzumab
1
naptumomab estafenatox
1
epacadostat
1
entinostat
1
cemiplimab
1
avelumab
1
atezolizumab
1
Thiotepa
1
Tamoxifen
1
Stem Cell Transplantation
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Mesna
1
Melphalan
1
Immunotherapy, Adoptive
1
Immune Checkpoint Inhibitors
1
Ifosfamide
1
Granulocyte Colony-Stimulating Factor
1
Fluorodeoxyglucose F18
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
regorafenib
×
Other solid neoplasm
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled